Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

The US Food and Drug Administration (FDA) has issued a partial hold on all ongoing clinical trials of venetoclax (Venclexta/Venclyxto, AbbVie) in the treatment of multiple myeloma, owing to an ...

Adding the targeted therapy venetoclax (Venclexta, AbbVie) to high-dose chemotherapy is a "step forward" for pediatric patients with relapsed or refractory acute myeloid leukemia (AML), says an ...

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing ...

Time-limited venetoclax-based combination therapies conferred superior rates of undetectable minimal residual disease compared with chemoimmunotherapy among fit patients with chronic lymphocytic ...

While venetoclax plus obinutuzumab received FDA approval in 2019 for less-fit CLL patients based on results of the CLL14 trial (showing superiority versus chlorambucil-obinutuzumab), ...

Venetoclax shows potential in pediatric relapsed/refractory AML/MDS, with a 41.6% overall response rate and 33% complete response rate in a single-center study.

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

The addition of venetoclax to azacitidine benefited untreated patients with isocitrate dehydrogenase mutations ineligible for intensive chemotherapy, according to study results presented at the ...

Venetoclax (Venclexta) combined with a hypomethylating agent (HMA) -- the standard of care for older patients with acute myeloid leukemia (AML) -- appeared to be safe and effective in patients in ...